Upgrade to SI Premium - Free Trial

BridgeBio Pharma (BBIO)

67.74 +0.19 (0.28%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/29/26)

Latest Headlines

BridgeBio Pharma (BBIO) PT Lowered to $87 at Morgan Stanley October 21, 2026 8:21 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $120 at Piper Sandler October 19, 2026 7:13 AM - StreetInsider BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) October 16, 2026 7:30 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $92 at UBS October 15, 2026 9:12 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO) October 15, 2026 6:57 AM - StreetInsider Form 8-K BridgeBio Pharma, Inc. For: Oct 06 October 13, 2026 6:03 AM - SEC Filing Truist Securitas's Biotechnology Earnings Preview: 'INSM, BBIO, NBIX Most Levered to the Print' October 12, 2026 9:04 AM - StreetInsider Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records October 11, 2026 2:30 PM - StreetInsider BridgeBio's encaleret shows symptom gains in ADH1 phase 3 trial October 11, 2026 11:42 AM - StreetInsider Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 October 11, 2026 11:42 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO) October 7, 2026 6:48 AM - StreetInsider Canaccord Reiterates Buy Rating on BridgeBio Pharma (BBIO) October 7, 2026 6:45 AM - StreetInsider BridgeBio Pharma (BBIO) PT Lowered to $156 at Barclays October 7, 2026 3:48 AM - StreetInsider BridgeBio to present encaleret trial data at ASBMR 2026 meeting October 6, 2026 4:01 PM - StreetInsider BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 October 6, 2026 4:01 PM - StreetInsider BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting October 6, 2026 4:01 PM - StreetInsider BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day October 6, 2026 12:58 PM - PR NewsWire William Blair: 'view BridgeBio as becoming a core smidcap biotech holding' October 6, 2026 10:46 AM - StreetInsider FDA accepts BridgeBio's NDA for oral infigratinib for achondroplasia October 6, 2026 7:30 AM - StreetInsider BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia October 6, 2026 7:30 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO) October 6, 2026 6:54 AM - StreetInsider BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day October 5, 2026 4:02 PM - StreetInsider BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day October 5, 2026 4:01 PM - StreetInsider Jefferies Reiterates Buy Rating on BridgeBio Pharma (BBIO) October 5, 2026 12:21 PM - StreetInsider TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) October 5, 2026 10:43 AM - StreetInsider BridgeBio Pharma (BBIO) Reiterated at Overweight by Cantor Fitzgerald October 5, 2026 7:44 AM - StreetInsider BridgeBio cardiac data shows BBP-418 benefit in muscle disease trial October 5, 2026 7:31 AM - StreetInsider BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels October 5, 2026 7:30 AM - StreetInsider 3 high-conviction SMID-cap biotech stocks to buy: Jefferies October 1, 2026 3:00 PM - StreetInsider Jefferies Highlights Three Biotech Stocks With Blockbuster Potential September 30, 2026 3:35 PM - StreetInsider Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening September 23, 2026 7:47 AM - Globe NewsWire Form 4 BridgeBio Pharma, Inc. For: Sep 17 Filed by: Kumar Neil September 21, 2026 6:21 PM - SEC Filing BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) September 18, 2026 4:01 PM - StreetInsider BridgeBio Pharma (BBIO) PT Lowered to $23 at JPMorgan September 11, 2026 8:43 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO) September 10, 2026 6:49 AM - StreetInsider BridgeBio reports infigratinib trial data on sleep apnea, ear infections September 9, 2026 4:00 AM - StreetInsider Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial September 9, 2026 4:00 AM - StreetInsider BridgeBio to present infigratinib data at ESPE meeting in September September 2, 2026 7:30 AM - StreetInsider BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 September 2, 2026 7:30 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO) September 2, 2026 6:55 AM - StreetInsider BridgeBio to Participate in September Investor Conferences September 1, 2026 7:30 AM - StreetInsider Trump announces nine more pharma firms in drug pricing deals August 31, 2026 3:08 PM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $110 at Mizuho August 31, 2026 1:59 PM - StreetInsider BridgeBio's acoramidis shows cardiac reversal data at ESC 2026 August 31, 2026 6:04 AM - StreetInsider Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM August 30, 2026 10:00 AM - StreetInsider BridgeBio doses first patient in Phase 3b/4 acoramidis heart study August 26, 2026 7:33 AM - StreetInsider BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM August 26, 2026 7:30 AM - StreetInsider BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026 August 24, 2026 7:30 AM - StreetInsider Form 4 BridgeBio Pharma, Inc. For: Aug 18 Filed by: Kumar Neil August 20, 2026 4:31 PM - SEC Filing Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil August 19, 2026 4:34 PM - SEC Filing Form 4 BridgeBio Pharma, Inc. For: Aug 16 Filed by: Trimarchi Thomas August 18, 2026 6:03 PM - SEC Filing Form 4 BridgeBio Pharma, Inc. For: Aug 16 Filed by: Kumar Neil August 18, 2026 6:03 PM - SEC Filing Form 4 BridgeBio Pharma, Inc. For: Aug 16 Filed by: Apuli Maricel August 18, 2026 6:02 PM - SEC Filing Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil August 18, 2026 4:27 PM - SEC Filing Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: KKR Genetic Disorder L.P. August 17, 2026 5:31 PM - SEC Filing Form 144 BridgeBio Pharma, Inc. Filed by: Scott Randal W. August 17, 2026 4:33 PM - SEC Filing Form 8-K BridgeBio Pharma, Inc. For: Aug 13 August 17, 2026 9:05 AM - SEC Filing KKR prices secondary offering of 5 million BridgeBio shares August 14, 2026 7:30 AM - StreetInsider BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base August 14, 2026 7:30 AM - StreetInsider Form 424B7 BridgeBio Pharma, Inc. August 14, 2026 6:51 AM - SEC Filing KKR to sell 5 million BridgeBio shares in secondary offering August 13, 2026 5:43 PM - StreetInsider BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder August 13, 2026 5:42 PM - Globe NewsWire BridgeBio Pharma (BBIO) PT Raised to $107 at Truist Securities August 12, 2026 7:15 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $111 at JPMorgan August 12, 2026 7:13 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $106 at Canaccord August 12, 2026 6:51 AM - StreetInsider BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) August 11, 2026 4:01 PM - StreetInsider Cantor Fitzgerald Reiterates Overweight Rating on BridgeBio Pharma (BBIO), Updates Estimates August 11, 2026 9:44 AM - StreetInsider BridgeBio Pharma (BBIO) PT Lowered to $97 at Morgan Stanley August 11, 2026 9:08 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $110 at TD Cowen August 11, 2026 8:04 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $115 at Piper Sandler as 'Attruby Outperforms' August 11, 2026 7:48 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $102 at Wells Fargo August 11, 2026 6:57 AM - StreetInsider BridgeBio Pharma (BBIO) PT Raised to $94 at Citi August 11, 2026 4:46 AM - StreetInsider BridgeBio Pharma Inc. (BBIO) Misses Q2 EPS by 18c August 10, 2026 4:33 PM - StreetInsider Form 10-Q BridgeBio Pharma, Inc. For: Jun 30 August 10, 2026 4:32 PM - SEC Filing Form 8-K BridgeBio Pharma, Inc. For: Aug 10 August 10, 2026 4:04 PM - SEC Filing BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates August 10, 2026 4:01 PM - StreetInsider Form 4 BridgeBio Pharma, Inc. For: Jul 30 Filed by: Apuli Maricel August 3, 2026 4:21 PM - SEC Filing Form SCHEDULE 13G/A BridgeBio Pharma, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C. August 3, 2026 8:31 AM - SEC Filing BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET August 3, 2026 7:30 AM - StreetInsider Form SCHEDULE 13G/A BridgeBio Pharma, Inc. Filed by: BlackRock, Inc. July 27, 2026 4:26 PM - SEC Filing Form S-3ASR BridgeBio Pharma, Inc. July 24, 2026 5:20 PM - SEC Filing Form S-8 BridgeBio Pharma, Inc. July 24, 2026 5:17 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO) July 24, 2026 7:26 AM - StreetInsider Full Article List